Version 1
: Received: 26 August 2019 / Approved: 27 August 2019 / Online: 27 August 2019 (16:34:22 CEST)
How to cite:
Ferreira, W.A.S.; Amorim, C.K.N.; Burbano, R.R.; Villacis, R.A..R.; Machi, F.A.; Medina, T.D.S.; de Oliveira, E.H.C. Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1. Preprints2019, 2019080288. https://doi.org/10.20944/preprints201908.0288.v1
Ferreira, W.A.S.; Amorim, C.K.N.; Burbano, R.R.; Villacis, R.A..R.; Machi, F.A.; Medina, T.D.S.; de Oliveira, E.H.C. Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1. Preprints 2019, 2019080288. https://doi.org/10.20944/preprints201908.0288.v1
Ferreira, W.A.S.; Amorim, C.K.N.; Burbano, R.R.; Villacis, R.A..R.; Machi, F.A.; Medina, T.D.S.; de Oliveira, E.H.C. Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1. Preprints2019, 2019080288. https://doi.org/10.20944/preprints201908.0288.v1
APA Style
Ferreira, W.A.S., Amorim, C.K.N., Burbano, R.R., Villacis, R.A..R., Machi, F.A., Medina, T.D.S., & de Oliveira, E.H.C. (2019). Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1. Preprints. https://doi.org/10.20944/preprints201908.0288.v1
Chicago/Turabian Style
Ferreira, W.A.S., Tiago da Silva Medina and Edivaldo Herculano Correa de Oliveira. 2019 "Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1" Preprints. https://doi.org/10.20944/preprints201908.0288.v1
Abstract
Cancer cell lines are widely used as in vitro models of tumorigenesis, facilitating fundamental discoveries in cancer biology and translational medicine. Currently, there are few options for glioblastoma (GBM) treatment and limited in vitro models with accurate genomic and transcriptomic characterization. Here, a detailed characterization of a new GBM cell line, namely AHOL1, was conducted in order to fully characterize its molecular composition based on its copy number alteration (CNA) and transcriptome profiling, followed by the validation of key elements associated with GBM tumorigenesis. Large numbers of CNAs and differentially expressed genes (DEGs) were identified. CNAs were distributed throughout the genome, including gains at Xq11.1-q28, Xp22.33-p11.1, Xq21.1-q21.33, 4p15.1-p14, 8q23.2-q23.3 and losses at Yq11.21-q12, Yp11.31-p11.2 and 12p13.31 positions. Nine druggable genes were identified, including HCRTR2, ETV1, PTPRD, PRKX, STS, RPS6KA6, ZFY, USP9Y and KDM5D. By integrating DEGs and CNAs, we identified 57 overlapping genes enriched in fourteen pathways. Altered expression of several cancer-related candidates found in the DEGs-CNA dataset was confirmed by RT-qPCR. Taken together, this first comprehensive genomic and transcriptomic landscape of AHOL1 provides unique resources for further studies and identifies several druggable targets that may be useful for therapeutics and biologic and molecular investigation of GBM.
Keywords
array-comparative genomic; gliomas; Cell culture; Cancer genomics; Cancer Transcriptomics; brain tumors; cell line; glioblastoma
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
(Click to see Publons profile: )
The commenter has declared there is no conflict of interests.
Comment:
I am quite surprised that a number of important information items regarding this cell line is not available:
- First and foremost a STR profile. This is now mandatory in many publications and anyone using this cell line would need to produce such an information with their manuscript.
- A sequence analysis of the most "popular" oncogenic mutations (especially IDH1/IDH2, PTEN, TP53, etc)
- The population doubling time
I hope these will be available once the paper is accepted in a journal.
PS: The entry for this cell line will be available in release 33 of the Cellosaurus (december 2019) under the accession number (RRID): CVCL_XH23
Commenter:
The commenter has declared there is no conflict of interests.
- First and foremost a STR profile. This is now mandatory in many publications and anyone using this cell line would need to produce such an information with their manuscript.
- A sequence analysis of the most "popular" oncogenic mutations (especially IDH1/IDH2, PTEN, TP53, etc)
- The population doubling time
I hope these will be available once the paper is accepted in a journal.
PS: The entry for this cell line will be available in release 33 of the Cellosaurus (december 2019) under the accession number (RRID): CVCL_XH23